CGEM
NASDAQ · Biotechnology
Cullinan Therapeutics Inc
$17.84
-0.11 (-0.61%)
Open$18.13
Previous Close$17.95
Day High$18.44
Day Low$17.52
52W High$19.43
52W Low$5.68
Volume—
Avg Volume540.5K
Market Cap1.09B
P/E Ratio—
EPS$-3.72
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+20.2% upside
Current
$17.84
$17.84
Target
$21.45
$21.45
$16.94
$21.45 avg
$32.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |
| Rev Growth | +6.1% | +12.8% | -3.3% |
| Debt/Equity | 0.08 | 0.08 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |